This is particularly important with chemotherapy agents that cause delayed acute emesis, such as cyclophosphamide and carboplatin. The ability of an antiemetic agent to provide such protection ...

This research aimed to identify genes involved in emesis and their expression in response to emetic and antiemetic agents, thereby enhancing the genomic resources available for emesis research[1].

When selecting an antiemetic, clinicians must select an agent that provides optimal protection against nausea and vomiting while avoiding drug-drug interactions and additional adverse events.

Recent research has explored various aspects of maropitant's use, including its pharmacokinetics, efficacy in different clinical scenarios, and comparisons with other antiemetic agents.